The Kansas VFW focused its opposition on Section 108 of the “Take Care of America’s Veterans Act,” which addresses sleep ...
The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.
The Hearty Soul on MSN
Sticking to One Simple Daily Habit Helped Man Drop 240lbs
One man lost 240lbs with a single daily habit weight loss strategy - walking. Here's what the science says about why it works ...
A new study from the University of Florida College of Medicine and the Johns Hopkins Bloomberg School of Public Health found that untreated sleep apnea is associated with a 69% faster decline in ...
Swindon's Great Western Hospital is one of five trust offering a new treatment for sleep apnoea.
Resmed remains the best performer of biotech's Big Four, but some investors aren't sleeping tight after last week's $700 ...
Cambridge biotech Apnimed has filed for an initial public offering as it awaits Food and Drug Administration approval for its ...
Apnimed is having sweet dreams of an IPO that could fund the planned commercial launch of an obstructive sleep apnea (OSA) therapy that is currently awaiting an FDA approval decision. The therapy, ...
Korea University Anam Hospital warns persistent tiredness may indicate anemia, thyroid disease, diabetes or chronic organ ...
AI analysis of snoring sounds may help identify the source of upper airway obstruction and support non-invasive sleep ...
Some companies are shifting towards influencer-style videos – but with regular customers and employees, not cultivated internet personalities.
Apnimed, a late-stage clinical pharmaceutical company, filed for an initial public offering in the U.S. on Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results